MassARRAY multigene screening combined with LDL-C and sdLDL-C detection for more favorable outcomes in type 2 diabetes mellitus therapy
Abstract Background To determine the clinical value of multigene polymorphisms, LDL-C and sdLDL-C on T2DM therapy. Methods In total, 352 T2DM patients before and after treatment and 48 healthy individuals were enrolled in this study. LDL-C and sdLDL-C were detected in 352 T2DM patients and 48 health...
Saved in:
Main Authors: | Yong Tian (Author), Junhong Wang (Author), Yanxiao Liu (Author), Xiangguang Luo (Author), Ziying Yao (Author), Xinjun Wang (Author), Yuanyuan Zhang (Author), Cheng Xu (Author), Xiaoyu Zhao (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2021-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dyslipidemia in subclinical hypothyroidism requires assessment of small dense low density lipoprotein cholesterol (sdLDL-C)
by: Saric Maida Seferovic, et al.
Published: (2017) -
Individualized initiation of statin therapy determined by baseline LDL-C: Are you more likely to achieve goal LDL-C?
by: James R Clem, et al.
Published: (2009) -
Implication of Low HDL-c Levels in Patients with Average LDL-c Levels: A Focus on Oxidized LDL, Large HDL Subpopulation, and Adiponectin
by: Filipa Mascarenhas-Melo, et al.
Published: (2013) -
Lifelong prevention of atherosclerotic cardiovascular disease (ASCVD) through LDL-C control - Means and cost/benefit of sustained very low lifetime LDL-C targets
by: Mayank Dalakoti, et al.
Published: (2024) -
OBICETRAPIB TARGETS ALL ATHEROGENIC LIPOPROTEINS BEYOND LDL-C
by: Michael Davidson, MD
Published: (2024)